1NCE Delivers Freedom From IoT Vendor Lock-In
1NCE, an IoT software and connectivity company available in 158 countries, today announced the launch of Freedom to Switch – the company’s future-proof answer to the vendor lock-in issues that plague the IoT industry.
1NCE embraces open standards as a part of the company’s core principles. At no additional cost, the company’s new Freedom to Switch feature offers customers peace of mind to make future changes during the lifetime of their devices. The company’s new industrial SIM cards and chips include eUICC technology that ensures 1NCE customers are prepared for any eventuality. Customers can now add or switch to another connectivity provider without having to touch their device – avoiding the costly expense of truck roll and field service.
“In IoT, scopes change and data insights evolve, so customers should always have the freedom to switch. 1NCE thinks it should be a fundamental right for customers to add or change a provider over the lifetime of an IoT project – even if that means leaving us,” said Ivo Rook, Chief Operating Officer at 1NCE.
Also new for 1NCE customers is the ability to create test profiles, which help optimize the supply chain by testing connectivity during manufacturing. The test profile is a unique type of operator profile that’s designed specifically for end-of-line tests. Without changing the SIM, customers can use AT commands to switch from the 1NCE profile to the test profile, perform necessary tests with a network emulator, then switch back before shipping the device. This allows function tests even in regions where 1NCE is not available.
The 1NCE Lifetime Flat subscription is industry-disruptive but simple: customers can deploy, connect, and manage IoT sensors across the world for as little as a dollar per year per device. Complimentary to all Lifetime Flat customers, 1NCE OS is enterprise-grade software that supports IoT projects of any scale, for new and existing projects alike. Using 1NCE OS for device and cloud integration, customers can accelerate time-to-market for IoT projects by months. It also features advanced remote access to device states and telemetry, device location without GPS and optimized payload transmission to increase battery life by up to 70 percent.
Customers can get started with 1NCE at the company’s online shop and on the AWS Marketplace. Customer support is available in 14 languages.
About 1NCE
1NCE is the only software and connectivity company delivering lifetime IoT for a global flat subscription. Our mission is to deliver true cross-border, future-proof IoT without uncertainty or hassle over the lifetime of a device. In 158 countries, 1NCE delivers connectivity like electricity ready for consumption – opening the world of IoT to innovators who will dramatically improve the environment, cities, healthcare, public safety, the supply chain and more. Learn more online and follow 1NCE on Twitter, LinkedIn and Facebook.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230814324787/en/
Contact information
Media Contact
Brad Chase // brad.chase@1NCE.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Enginzyme and AGC Create Scalable Process for Key mRNA Ingredient12.1.2026 07:00:00 EET | Press release
At the mRNA Health conference in Berlin, enginzyme and AGC Inc. presented a scalable process to produce a key mRNA vaccine and therapy ingredient, N1-methylpseudouridine-5'-triphosphate (m¹ΨTP). The rapid growth of mRNA-based vaccines and therapeutics has driven significant demand for modified nucleotides like m¹ΨTP, which enhances mRNA stability and expression, while reducing immunogenicity. Enginzyme is a deep-tech company delivering optimized biomanufacturing solutions through cell-free enzyme engineering technology. AGC Inc. is a leading global player in fields spanning from architectural glass to chemicals and life science. AGC Inc. provides services in a wide range of life science fields, from synthetic pharmaceuticals and agrochemicals, to biopharmaceuticals and leading-edge cell and gene therapies, as well as messenger RNAs. The presentation in November detailed the latest collaboration between the companies, with a focus on the biomanufacturing of nucleotides for mRNA therapy,
Ant International Partners with Google’s Universal Commerce Protocol to Expand AI Capabilities12.1.2026 03:15:00 EET | Press release
Ant International, a leading global payment, digitisation, and financial technology provider, is collaborating on the launch of Google’s Universal Commerce Protocol (UCP), a new open standard for agentic commerce that works across the entire shopping journey — from discovery and buying to post-purchase support. UCP establishes a common language for agents and systems to operate together across consumer surfaces, businesses, and payment providers to enable commerce. So instead of requiring unique connections for every individual agent, UCP enables all agents to interact easily. UCP is built to work across verticals and is compatible with existing industry protocols like Agent2Agent (A2A), Agent Payments Protocol (AP2), and Model Context Protocol (MCP). “For agentic commerce to scale, it’s critical for the industry to align on a common set of standards. We are proud to have Ant International endorse the Universal Commerce Protocol as the foundation for that future,” said Ashish Gupta, VP
Torq Secures $140M Series D at $1.2B Valuation to Lead the AI SOC and Agentic AI Era11.1.2026 18:59:00 EET | Press release
Torq, the established Agentic AI security operations pioneer, today announced it has closed a massive $140 million Series D funding round, propelling its valuation to $1.2 billion and total funding to $332M. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112510774/en/ Led by Merlin Ventures—a leading cybersecurity fund renowned for its deep access to the U.S. commercial and Public Sector markets—with participation from all existing investors, including Evolution Equity Partners, Notable Capital, Bessemer Venture Partners, Insight Ventures Partners, and Greenfield Partners, this capital injection is a definitive investment in the future of security. Torq is driving the industry’s critical shift: the complete transformation of the Security Operations Center (SOC) through battle-tested AI Agents at enterprise scale. The new funds will accelerate the adoption of the Torq AI SOC Platform, the only end-to-end solution built on
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 14:00:00 EET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreement were not disclosed. “This new agreement builds upon our recent co-development collaboration with Acepodia, which has focused on the evaluation and selection
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 12:08:00 EET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom